HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)
Forecasted
NIH funds milestone-driven research to develop, pilot, and expand testing of HIV prevention interventions, including approaches addressing alcohol use and related comorbidities.
Funder: National Institutes of Health
Due Dates (Anticipated): September 2027 (Estimated application deadline)
Funding Amounts: R61/R33 phased grant support; no cost sharing or matching required
Summary: Supports milestone-driven HIV prevention research, from intervention development and feasibility testing to expanded evaluation integrating alcohol use and related comorbidities.
Key Information: Progression to R33 expanded testing requires successful completion of R61 milestones; clinical trials are optional.
Description
The National Institutes of Health supports milestone-driven research through the R61/R33 Phased Innovation Award to advance innovative HIV prevention interventions. The program moves research from development and feasibility testing toward larger-scale efficacy, effectiveness, implementation, and dissemination studies. Its scope includes novel or enhanced HIV prevention and treatment strategies, including integrated approaches addressing alcohol use and related comorbidities.
The R61 phase supports development, refinement, adaptation, and pilot testing, addressing scientific, operational, or implementation questions needed to establish readiness for larger-scale evaluation. Projects may optimize intervention design, delivery, and implementation across diverse populations and settings. The R33 phase supports expanded testing of interventions and implementation strategies that have met R61 milestones, including studies of effectiveness, scalability, sustainability, clinical management, and delivery.
